AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice

Cany, Jeannette; Barteau, Benoit; Tran, Lucile; Gauttier, Vanessa; Archambeaud, Isabelle; Couty, Jean-Pierre; Turlin, Bruno; Pitard, Bruno; Vassaux, Georges; Ferry, Nicolas; Conchon, Sophie

doi:10.1016/j.jhep.2010.06.027

Cited by 38 publications

(41 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Stock solutions were prepared at 20% (w/v) in water and stored at 4°C. Formulations of DNA with 704 (final concentration 0.3%) were prepared immediately prior to intramuscular injection by equivolumetric mixing of copolymers in water with plasmid DNA solution as previously described [25], [26]. DNA doses administered are indicated throughout the study.…”

Section: Methodsmentioning

confidence: 99%

CCL5 Neutralization Restricts Cancer Growth and Potentiates the Targeting of PDGFRβ in Colorectal Carcinoma

et al. 2011

Self Cite

View full text Add to dashboard Cite

Increased CCL5 levels are markers of an unfavourable outcome in patients with melanoma, breast, cervical, prostate, gastric or pancreatic cancer. Here, we have assessed the role played by CCL5/CCR5 interactions in the development of colon cancer. To do so, we have examined a number of human colorectal carcinoma clinical specimens and found CCL5 and its receptors over-expressed within primary as well as liver and pulmonary metastases of patients compared to healthy tissues. In vitro, CCL5 increased the growth and migratory responses of colon cancer cells from both human and mouse origins. In addition, systemic treatment of mice with CCL5-directed antibodies reduced the extent of development of subcutaneous colon tumors, of liver metastases and of peritoneal carcinosis. Consistently, we found increased numbers of CD45-immunoreactive cells within the stroma of the remaining lesions as well as at the interface with the healthy tissue. In contrast, selective targeting of CCR5 through administration of TAK-779, a CCR5 antagonist, only partially compromised colon cancer progression. Furthermore, CCL5 neutralization rendered the tumors more sensitive to a PDGFRβ-directed strategy in mice, this combination regimen offering the greatest protection against liver metastases and suppressing macroscopic peritoneal carcinosis. Collectively, our data demonstrate the involvement of CCL5 in the pathogenesis of colorectal carcinoma and point to its potential value as a therapeutic target.

show abstract

Section: Methodsmentioning

confidence: 99%

CCL5 Neutralization Restricts Cancer Growth and Potentiates the Targeting of PDGFRβ in Colorectal Carcinoma

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…80% of primary liver cancers express a high rate of alpha-fetoprotein (AFP), which may act as a target for cancer therapy [3][4][5]. AFP is an oncofetal antigen during HCC progression which could induce weak reproducible antitumor effect.…”

Section: Discussionmentioning

confidence: 99%

Anti-tumor Effects Elicited by Heat Shock Protein 72 Functional Peptide and Alpha-fetoprotein Epitope Peptide Vaccine

Wang¹,

Wang²,

Xu³

et al. 2017

Proceedings of the 2017 7th International Conference on Education, Management, Computer and Society (EMCS 2017)

View full text Add to dashboard Cite

“…In another study, three immunizations with bone marrow-derived DCs expressing mouse AFP only protected one out of four mice from AFP-positive tumor challenge [35]. Mouse AFP DNA formulated with cationic polymers generated moderate T-cell responses, although a more pronounced antitumor overall effect was observed [38]. Xenogenic AFP peptides [41] or proteins [42] have also been used to increase AFP-specific immune responses.…”

Section: Current Cellular Immune Approaches For Hcc Immunotherapymentioning

confidence: 99%

Engineering α-fetoprotein-based Gene Vaccines to Prevent and Treat Hepatocellular Carcinoma: Review and Future Prospects

Yuan

Mizejewski

2014

Immunotherapy

View full text Add to dashboard Cite

Activation of a patient’s immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/ tumor antigens. We recently found that epitope-optimized α-fetoprotein effectively activated CD8 T cells and generated potent antitumor effects in the carcinogen-induced autochthonous HCC mouse model. We predict that the same antigen engineering approach of epitope-optimization will enable us to develop effective human vaccines to prevent HCC recurrence after liver resection. The engineered human HCC vaccines may also allow us to identify high-affinity T-cell receptors and antibodies that can be used to reprogram T cells to treat HCC tumors via adoptive transfer.

show abstract

AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice

Cited by 38 publications

References 31 publications

CCL5 Neutralization Restricts Cancer Growth and Potentiates the Targeting of PDGFRβ in Colorectal Carcinoma

CCL5 Neutralization Restricts Cancer Growth and Potentiates the Targeting of PDGFRβ in Colorectal Carcinoma

Anti-tumor Effects Elicited by Heat Shock Protein 72 Functional Peptide and Alpha-fetoprotein Epitope Peptide Vaccine

Engineering α-fetoprotein-based Gene Vaccines to Prevent and Treat Hepatocellular Carcinoma: Review and Future Prospects

Contact Info

Product

Resources

About